1720 — Standard Chem & Pharm Co Income Statement
0.000.00%
Last trade - 00:00
- TWD10.88bn
- TWD12.77bn
- TWD6.24bn
- 81
- 62
- 68
- 86
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,937 | 4,305 | 4,604 | 5,851 | 6,240 |
Cost of Revenue | |||||
Gross Profit | 1,709 | 1,920 | 2,068 | 2,488 | 2,725 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 3,421 | 3,599 | 3,729 | 4,733 | 4,937 |
Operating Profit | 516 | 707 | 875 | 1,118 | 1,302 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 586 | 773 | 1,014 | 1,400 | 1,438 |
Provision for Income Taxes | |||||
Net Income After Taxes | 470 | 626 | 837 | 1,154 | 1,158 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 376 | 524 | 707 | 815 | 835 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 376 | 524 | 707 | 815 | 835 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.15 | 2.93 | 3.62 | 4.59 | 4.47 |
Dividends per Share |